Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Used When Dementia Medications Fail? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

When standard dementia treatments like donepezil, rivastigmine, galantamine, or memantine stop working, families often ask whether medical cannabis might help. According to NHS and NICE guidance, the answer for now is no: cannabis-based medicinal products (CBMPs) are not used as standard care for dementia symptoms such as agitation, poor sleep, or appetite loss. 

Can medical cannabis be accessed legally for women’s health?

What The Evidence Shows 

NICE guidance on Cannabis-based Medicinal Products (NG144) explains that there is insufficient robust evidence to support medical cannabis for behavioural or psychological symptoms of dementia. It recommends that CBMPs be used only in research settings, not in routine NHS care. 

The NHS also states that medical cannabis is not an approved treatment for dementia, highlighting the lack of high-quality evidence and safety concerns for older adults, including confusion, sedation, and an increased risk of falls. 

What Research Says 

According to the Alzheimer’s Society UK, research on medical cannabis and dementia remains limited and inconclusive. Some small early trials have shown minor improvements in agitation, but overall results are mixed and unreliable. No consistent benefit has been found when approved dementia drugs have failed. 

Ongoing UK and EU studies, including projects supported by Alzheimer’s Research UK, continue to explore whether cannabinoids might reduce agitation or improve sleep, but findings so far have not led to regulatory approval. Reviews by Cochrane Dementia and Cognitive Improvement Group (2022) and recent systematic reviews such as Ryskina et al., 2024, Frontiers in Aging Neuroscience reach similar conclusions: evidence remains weak, inconsistent, and requires more rigorous trials. 

The Clinical Bottom Line 

  • Cannabis-based medicinal products are not routinely prescribed for dementia in the UK. 
  • NICE and NHS recommend CBMPs only within clinical research settings. 
  • Evidence for benefits such as reduced agitation or improved sleep is weak and inconsistent. 
  • Risks for older adults include sedation, confusion, and falls. 
  • Families should seek clinical advice before considering participation in research trials. 

What This Means in Practice 

For now, medical cannabis is not prescribed in the UK for dementia when other drugs no longer work. Enrolment in a regulated clinical trial is the only setting where CBMPs might be considered, under medical supervision. 

About AlleviMed 

Organisations such as AlleviMed provide educational information about how UK eligibility for medical cannabis is assessed, helping families understand the difference between licensed, research, and unregulated products, but not offering prescribing services. 

Takeaway 

At present, cannabis is not a proven or approved option for dementia symptoms when licensed medications fail. According to NICE, NHS, and the Alzheimer’s Society, its use should remain within research settings until stronger; safety-tested evidence becomes available. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories